

# **Data Sheet**


Product Name: Marein

Cat. No.:CS-0135183CAS No.:535-96-6Molecular Formula: $C_{21}H_{22}O_{11}$ Molecular Weight:450.39

Target: AMPK; HDAC

Pathway: Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

Solubility: DMSO: 25 mg/mL (55.51 mM; Need ultrasonic)



## **BIOLOGICAL ACTIVITY:**

Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the **AMPK signal pathway**. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a **HDAC** inhibitor with an **IC**<sub>50</sub> of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects<sup>[1][2][3]</sup>. IC50 & Target: IC50: 100 μM (HDAC)<sup>[3]</sup> *In Vitro:* Marein (0-1000 μM; 24 h) inhibits HDAC activity and TNF α-induced NF-κB activation with IC<sub>50</sub> values of 100 and >200 μM, respectively<sup>[1]</sup>.

Marein (1.25-40 μM; 24 h) promotes glucose uptake in HepG2 cells<sup>[2]</sup>.

Marein (5-10  $\mu$ M; 24 h) promotes GLUT1 translocation from intercellular vesicles to the plasma membrane, increases hepatic glycogen content and down-regulates expression levels of G6Pase and PEPCK in HepG2 cells<sup>[2]</sup>.

Marein (5-10  $\mu$ M; 24 h) stimulates 2-NBDG uptake, and it can be reduced by STO-609 and compound C which is a inhibitor of AMPK [2]

Marein (0-40 µM; 24 h) affects the cytotoxicity of MG in PC12 cells<sup>[3]</sup>.

#### References:

- [1]. Baoping Jiang, et al. Protective effects of marein on high glucose-induced glucose metabolic disorder in HepG2 cells. Phytomedicine. 2016 Aug 15;23(9):891-900.
- [2]. Baoping Jiang, et al. Marein protects against methylglyoxal-induced apoptosis by activating the AMPK pathway in PC12 cells. Free Radic Res. 2016;50(11):1173-1187.
- [3]. B Orlikova, et al. Natural chalcones as dual inhibitors of HDACs and NF-kB. Oncol Rep. 2012 Sep;28(3):797-805.

## **CAIndexNames:**

2-Propen-1-one, 3-(3,4-dihydroxyphenyl)-1-[4-(β-D-glucopyranosyloxy)-2,3-dihydroxyphenyl]-, (2E)-

# SMILES:

O = C(C1 = CC = C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)O(O) = C1O)/C = C/C3 = CC = C(O)C(O) = C3O(O) = C3O(O)

Page 1 of 2 www.ChemScene.com

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com